Small RCT with 32 ivermectin patients and 30 control patients. The mean recovery time after enrolment in the intervention arm was 5.31 ± 2.48 days vs. 6.33 ± 4.23 days in the control arm, p > 0.05. Negative PCR results were not significantly different between control and intervention arms, p>0.05. We are not sure what the results were because the abstract and Table 5 have switched the results.
Abstract: Original Article
Outcome of ivermectin treated mild to moderate COVID-19 cases:
a single-centre, open-label, randomised controlled study
Chinmay Saha Podder , Nandini Chowdhury , Mohim Ibne Sina , Wasim Md Mohosin Ul Haque
Debidwar Upazila Health Complex, Debidwar, Comilla, Bangladesh; Department of Nephrology, BIRDEM
General Hospital, Dhaka, Bangladesh
Background and objectives: Various existing non-antiviral drugs are being used to treat severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based mostly on existing data
from previous coronavirus outbreaks. Ivermectin is one of such agents being widely used to
treat early-stage of COVID-19. This study evaluated the outcome of ivermectin treated mild to
moderate COVID-19 cases compared to usual care.
Methods: This open-label randomised controlled study was conducted at a sub-district (Upazila)
health complex from 1st May 2020 to the end of July 2020. Consecutive RT-PCR positive eligible
COVID-19 patients were randomised into control and intervention arms. In the intervention
arm, ivermectin 200 micrograms/kg single dose was administered orally in addition to usual
care and was followed up till recovery. Repeat RT-PCR was done on day ten since the first
positive result. The end point with regard to treatment outcome was time required for the
resolution of symptoms from the onset of the symptoms and following enrollement in the
Results: A total of 62 mild to moderate COVID-19 patients were enrolled in the study. There
were 30 patients in the control arm and 32 patients in the intervention arm. Total recovery time
from the onset of symptoms to complete resolution of symptoms of the patients in the
intervention arm was 10.09 ± 3.236 days, compared to 11.50 ± 5.32 days in the control arm
(95% CI -0.860,3.627, p>. 05) and was not significantly different. The mean recovery time after
enrolment in the intervention arm was 5.31 ± 2.48 days, which also did not differ significantly
from the control arm of 6.33 ± 4.23 days (95% CI – 0.766, 2.808, p> 0.05). Results of negative
repeat RT- PCR were not significantly different between control and intervention arms (control
90% vs intervention 95%, p>.05).
Conclusion: Ivermectin had no beneficial effect on the disease course over usual care in mild to
moderate COVID-19 cases.
IMC J Med Sci 2020; 14(2): 002. EPub date: 03 September 2020
Late treatment is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.